Sale

Erythema Market

Erythema Market Size, Share, Outlook, Report, Forecast: By Type: Erythema Multiforme, Erythema Nodosum, Erythema Ab Igne, Erythema Chronicum Migrans, Erythema Induratum, Erythema Infectiosum, Erythema Marginatum, Others: By Drug Class, By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Erythema Market Outlook

The erythema market size in the 7 major markets was valued at USD 178.9 million in 2023, driven by rising incidence of cancer across the major markets. The market is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032, with the values likely to rise from USD 189.3 million in 2024 to USD 297.7 million by 2032.

 

Erythema: Introduction

Erythema is a wide category of skin condition, characterized by abnormal redness on the skin or mucous membranes. Hyperemia (increased blood) in superficial capillaries is one of the major causes of the condition. It may be an inflammatory response to an infection, massage, drug or medication, acute radiation syndrome, and mercury toxicity, among others. Erythema is of multiple types, with the most common symptoms being circular red bumps, itchiness, blisters, fever, or joint pain.

 

Erythema Market Analysis

Erythema is a common side effect of chemotherapy; therefore, the rising incidence of cancer cases has directly impacted the erythema market growth in recent years. Consequently, there has been significant emphasis on alleviating the chemotherapy associated symptoms with the help of novel therapeutics. In January 2023, it was revealed that high doses of vitamin D may function as an effective treatment alternative for the condition.

 

Erythema can be classified into several categories, including erythema multiform, nodosum, and chronicum migraines, among others. The treatment and management differ from condition to condition. Minor diseases are commonly treated with oral antihistamines or topical corticosteroids, whereas severe conditions are treated through systemic steroids.

 

To tackle recurrent erythema multiform (REM), several trials and developments are going on. As per studies, Azathioprine is one of the many immunosuppressive agents reported to be helpful for unresponsive REM cases to other treatments. With increasing understanding of the human physiology and growing technical advancements, the erythema market value is projected to grow in the forecast period.

 

Erythema Market Segmentation

Market Breakup by Type

  • Erythema Multiforme
  • Erythema Nodosum
  • Erythema Ab Igne
  • Erythema Chronicum Migrans
  • Erythema Induratum
  • Erythema Infectiosum
  • Erythema Marginatum
  • Erythema Toxicum
  • Erythema Gyratum Repens
  • Palmar Erythema
  • Erythema Annulare Centrifugum

 

Market Breakup by Drug Class

  • Antibiotics
  • Antihistamines
  • Analgesics
  • NSAIDs
  • Corticosteroid
  • Antiviral
  • Antifungal
  • Antibacterial

 

Market Breakup by Route of Administration

  • Oral
  • Topical
  • Intravenous
  • Others

 

Market Breakup by End User

  • Hospital and Clinics
  • Ambulatory Clinics
  • Others

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Erythema Market Overview

With a significance on skin health and meeting the high erythema market demand, the United States has experienced critical developments in recent years. The enhancements can be attributed to the presence of key healthcare companies and a well-established infrastructure, contributing extensively to market value.

 

The rising prevalence of skin conditions drives the market growth in Europe as well. Countries like the United Kingdom, Italy, Germany, and France are some of the key regions offering quality treatments, owing to the presence of prominent research and academic institutions. Mergers and collaborations between key pharmaceutical companies and academic organizations is another important factor for the market size.

 

The Asia Pacific region, particularly countries like Japan, China, India, and South Korea are also affected by a huge demand. With an affluential traditional medicinal therapy history, the countries are also developing herbal medications for the condition. On the other hand, there have been continuous efforts to improve the healthcare infrastructure for better research and development. Therefore, the region is anticipated to contribute significantly to the erythema market share globally as well.

 

Erythema Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • GSK plc. (U.S.)
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Astrazeneca
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Abbvie
  • Amgen Inc.
  • AB Sciences
  • Eisai Co., Ltd
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Valeant Pharmaceuticals International Inc.
  • Bausch Health Companies Inc.
  • Enzon Pharmaceuticals

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Drug Class
  • Route of Administration
  • End User
  • Region
Breakup by Type
  • Erythema Multiforme
  • Erythema Nodosum
  • Erythema Ab Igne
  • Erythema Chronicum Migrans
  • Erythema Induratum
  • Erythema Infectiosum
  • Erythema Marginatum
  • Erythema Toxicum
  • Erythema Gyratum Repens
  • Palmar Erythema
  • Erythema Annulare Centrifugum
Breakup by Drug Class
  • Antibiotics
  • Antihistamines
  • Analgesics
  • NSAIDs
  • Corticosteroid
  • Antiviral
  • Antifungal
  • Antibacterial
Breakup by Route of Administration
  • Oral
  • Topical
  • Intravenous
  • Others
Breakup by End User
  • Hospital and Clinics
  • Ambulatory Clinics
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • GSK plc. (U.S.)
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Astrazeneca
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Abbvie
  • Amgen Inc.
  • AB Sciences
  • Eisai Co., Ltd
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Valeant Pharmaceuticals International Inc.
  • Bausch Health Companies Inc.
  • Enzon Pharmaceuticals

 

Our Top Selling Reports

Teleradiology Market

Lancet Market

Breathalyzers Market

Human Insulin Market

Perineal Care Market

Anaemia Drugs Market

Sigmoidoscope Market

Cancer Biopsy Market

Stents Market

legal Marijuana Market

 

Erythema Market Report Snapshots

Erythema Market Size

Erythema Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Erythema Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Erythema Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Erythema Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Erythema Epidemiology Forecast (2017-2032)
        5.3.1    Germany Erythema Epidemiology Forecast (2017-2032)
        5.3.2    France Erythema Epidemiology Forecast (2017-2032)
        5.3.3    Italy Erythema Epidemiology Forecast (2017-2032)
        5.3.4    Spain Erythema Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Erythema Epidemiology Forecast (2017-2032)
    5.4    Japan Erythema Epidemiology Forecast (2017-2032)
6    Erythema Market Overview – 7MM
    6.1    Erythema Market Historical Value (2017-2023) 
    6.2    Erythema Market Forecast Value (2024-2032)
7    Erythema Market Landscape – 7MM
    7.1    Erythema: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Erythema Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by Drug Class
8    Erythema Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Erythema Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Erythema Market Segmentation – 7MM
    11.1     Erythema Market by Type
        11.1.1    Market Overview
        11.1.2    Erythema Multiforme
        11.1.3    Erythema Nodosum
        11.1.4    Erythema Ab Igne
        11.1.5    Erythema Chronicum Migrans
        11.1.6    Erythema Induratum
        11.1.7    Erythema Infectiosum
        11.1.8    Erythema Marginatum
        11.1.9    Erythema Toxicum
        11.1.10    Erythema Gyratum Repens
        11.1.11    Palmar Erythema
        11.1.12    Erythema Annulare Centrifugum
    11.2    Erythema Market by Drug Class
        11.2.1    Market Overview
        11.2.2    Antibiotics
        11.2.3    Antihistamines
        11.2.4    Analgesics
        11.2.5    NSAIDs
        11.2.6    Corticosteroid
        11.2.7    Antiviral
        11.2.8    Antifungal
        11.2.9    Antibacterial
    11.3    Erythema Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Topical
        11.3.4    Intravenous
        11.3.5    Others
    11.4    Erythema Market by End User 
        11.4.1    Market Overview
        11.4.2    Hospital and Clinics
        11.4.3    Ambulatory Clinics
        11.4.4    Others
    11.5    Erythema Market by Region
        11.5.1    Market Overview
        11.5.2    United States
        11.5.3    EU-4 and the United Kingdom
            11.5.3.1    Germany 
            11.5.3.2    France 
            11.5.3.3    Italy 
            11.5.3.4    Spain
        11.5.4    Japan
12    United States Erythema Market
    12.1    Erythema Market Historical Value (2017-2023) 
    12.2    Erythema Market Forecast Value (2024-2032)
        12.2.1    Erythema Market by Disease Type
        12.2.2    Erythema Market by Drug Class
13    EU-4 and United Kingdom Erythema Market
    13.1    Erythema Market Historical Value (2017-2023) 
    13.2    Erythema Market Forecast Value (2024-2032)
    13.3    Germany Erythema Market Overview
        13.3.1    Erythema Market by Disease Type
        13.3.2    Erythema Market by Drug Class  
    13.4    France Erythema Market Overview
        13.4.1    Erythema Market by Disease Type
        13.4.2    Erythema Market by Drug Class
    13.5    Italy Erythema Market Overview
        13.5.1    Erythema Market by Disease Type
        13.5.2    Erythema Market by Drug Class
    13.6    Spain Erythema Market Overview
        13.6.1    Erythema Market by Disease Type
        13.6.2    Erythema Market by Drug Class
    13.7    United Kingdom Erythema Market Overview
        13.7.1    Erythema Market by Disease Type
        13.7.2    Erythema Market by Drug Class
14    Japan Erythema Market
    14.1    Erythema Market Historical Value (2017-2023) 
    14.2    Erythema Market Forecast Value (2024-2032)
        14.2.1    Erythema Market by Disease Type
        14.2.2    Erythema Market by Drug Class
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
    15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1     Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    GSK plc. (U.S.)
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    F. Hoffmann-La Roche Ltd
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    Novartis AG
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    Astrazeneca
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    Pfizer Inc.
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
    20.6    Bristol-Myers Squibb Company
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
    20.7    Abbvie
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    Amgen Inc.
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    AB Sciences
        20.9.1    Financial Analysis
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    Eisai Co., Ltd
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    Regeneron Pharmaceuticals Inc.
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    Sanofi S.A.
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Valeant Pharmaceuticals International Inc.
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Bausch Health Companies Inc.
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
    20.15    Enzon Pharmaceuticals
        20.15.1    Financial Analysis
        20.15.2    Product Portfolio
        20.15.3    Demographic Reach and Achievements
        20.15.4    Mergers and Acquisition
        20.15.5    Certifications
21    Erythema Market - Distribution Model (Additional Insight)
    21.1    Overview 
    21.2    Potential Distributors 
    21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)

    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket

 
*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 178.9 million in 2023, driven by growing incidence of cancer across the globe.

The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, likely to reach a market value of USD 297.7 million by 2032.

The market demand is driven by the increasing drug developments and trials to offer better patient outcomes.

The market trend involves the increasing focus on developing personalised medicine for patients. High dosage of vitamin D is being administered to patients to minimise the chemotherapy associated side effects.

Based on types, the market is divided into erythema multiforme, nodosum, ab igne, chronicum migrans, induratum, infectiosum, marginatum, toxicum, gyratum repens, palmar erythema and annulare centrifugum.

Common mechanism of action includes antibiotics, antihistamines, analgesics, NSAIDs, corticosteroid, antiviral, antifungal and antibacterial.

Major end users include hospitals, clinics, and ambulatory clinics, among others.

The route of administration can be oral, topical, intravenous among others.

The major regions of the market include the United States, Japan, EU-4, which is segmented into Germany, France, Italy, Spain, and the United Kingdom.

Key players involved in the market are GSK plc. (U.S.), F. Hoffmann-La Roche Ltd., Novartis AG, Astrazeneca, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi, Amgen Inc., AB Sciences, Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Bausch Health Companies Inc., and Enzon Pharmaceuticals.

Analyst Review

 

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER